Dynamic Technology Lab Private Ltd Increases Stock Holdings in Repligen Corporation $RGEN

Key Points

• Dynamic Technology Lab Private Ltd significantly increased its stake in Repligen Corporation by 233.6% during the first quarter, holding 9,208 shares valued at approximately $1.17 million.
• Several institutional investors have also raised their positions, with 97.64% of Repligen's stock owned by hedge funds and institutional investors.
• Repligen's stock has received multiple "overweight" ratings from analysts, with a consensus target price of $169.55 amid recent performance showing revenue growth of 14.8% year-over-year.

Dynamic Technology Lab Private Ltd boosted its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 233.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,208 shares of the biotechnology company's stock after purchasing an additional 6,448 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Repligen were worth $1,172,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in RGEN. Point72 Asset Management L.P. raised its holdings in Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock worth $962,711,000 after purchasing an additional 430,039 shares in the last quarter. Nuveen LLC bought a new position in Repligen in the first quarter worth $35,536,000. Artemis Investment Management LLP raised its holdings in Repligen by 110.1% in the first quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock worth $41,128,000 after purchasing an additional 169,397 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Repligen by 17,721.1% in the first quarter. GAMMA Investing LLC now owns 121,896 shares of the biotechnology company's stock worth $15,510,000 after purchasing an additional 121,212 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on RGEN shares. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Evercore ISI decreased their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Barclays started coverage on Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Wells Fargo & Company cut their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research note on Tuesday, September 2nd. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $166.67.

Repligen Stock Performance

Shares of Repligen stock traded down $5.97 during trading on Friday, hitting $113.54. 707,503 shares of the company's stock traded hands, compared to its average volume of 665,349. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The stock has a market capitalization of $6.39 billion, a P/E ratio of -454.14, a PEG ratio of 2.20 and a beta of 1.07. The business has a 50-day simple moving average of $120.73 and a 200-day simple moving average of $127.78.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the business earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the company's stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.